October 9th 2024
The vaccine proved a cumulative efficacy of 62.9% against respiratory syncytial virus-related lower respiratory tract disease in older adults over three seasons.
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
October 26, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
6th Annual Advanced Practice Collaborative
View More
Community Practice Connections™: 24th Annual International Lung Cancer Congress®
View More
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations
View More
Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema
View More
Shaping the Management of COPD with Biologic Therapy
View More
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
EGPA: Highlighting the Patient Journey to Improve the Differential Diagnosis and Accelerate the Initiation of Guideline-Based Care
View More
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today
View More
Clinical ShowCase™: Finding the Best Path Forward for Patients with COPD
View More
Charting the Path to Precision Diagnosis: Detection and Treatment Approaches for Oncogenic Mutations in NSCLC
View More
Community Practice Connections™: The 2nd Annual Hawaii Lung Cancers Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Testing Procalcitonin Levels to Guide Antimicrobial Stewardship
April 21st 2022Investigators used procalcitonin (PCT) levels to guide antibiotic recommendations in pediatric intensive care units. PCT-guided antibiotic stewardship decreased the number of antibiotic days without leading to therapy failure.
Read More
Few Readmissions After Hospitalization for CAP Are Avoidable
April 18th 2022An analysis of readmissions after hospitalization with community-acquired pneumonia (CAP) in France found that few readmissions were avoidable, supporting criticism that the measure may lead to unfair penalties under pay-for-performance programs.
Read More
Did Full FDA Approval of the Pfizer-BioNTech Vaccine Increase COVID-19 Vaccinations?
April 6th 2022After the US Food and Drug Administration (FDA) fully authorized the Pfizer-BioNTech mRNA vaccine, series-completing second doses increased substantially. However, first vaccine doses were actually administered at lower rates after the approval.
Read More
In Children Under 5, Omicron COVID-19 Infection Was More Likely, But Delta Was More Severe
April 2nd 2022Children under 5 became infected with the Omicron variant 6-8 times more frequently than young children who contracted Delta. However, Delta COVID-19 infections were more severe than Omicron.
Read More
NIH Launches Trial Evaluating Second COVID-19 Booster Shots
March 31st 2022One day after the FDA approved second booster shots for certain vulnerable populations, the National Institute of Health (NIH) announced they have begun enrolling adult US participants in a phase 2 clinical trial to evaluate a second COVID-19 booster dose.
Read More
Sotrovimab Distribution Paused in Areas Where BA.2 Is Dominant COVID-19 Variant
March 28th 2022The Assistant Secretary for Preparedness and Response (ASPR) announced a pause in sotrovimab distribution in regions where BA.2 is the dominant COVID-19 variant, citing evidence that the monoclonal antibody therapy would not effectively neutralize the BA.2 Omicron variant.
Read More
Type 2 Diabetes Diagnosis More Likely After COVID-19 Infection
March 21st 2022A matched cohort study found COVID-19 infection increased the risk of new type 2 diabetes diagnosis. Compared to patients with acute upper respiratory tract infections, COVID-19 patients were 28% more likely to develop diabetes.
Read More
“Most Transmissible Variant” BA.2 Expected to Overtake Original Omicron Strain
March 21st 2022There are many unknowns about the BA.2 COVID-19 variant. It appears 50-60% more transmissible than the original Omicron variant, but health experts are mixed on whether cases will spike dramatically.
Read More
Children’s Duration of COVID-19 Immunity from Natural Infection
March 19th 2022A Texas study found children and adolescents who previously contracted COVID-19 retained protective antibodies for 6 or more months after infection. However, natural infection plus vaccination remains the best defense against COVID-19.
Read More
With New Variants, COVID-19 Vaccination Mildly Effective in Children
March 15th 2022In children and adolescents, the Pfizer-BioNTech vaccine was only mildly effective against symptomatic and asymptomatic COVID-19 infections. Broken down by variant, Omicron infections were more likely to occur and more likely to be asymptomatic.
Read More